Stereotactic body radiation therapy for centrally-located lung tumors

作者：Shen, Ge^*; Wang, Ying-Jie; Shen, Wen-Jiang; Zhou, Zhen-Shan; Wang, Jun-Liang; Sheng, Hong-Guo; Dong, Da-Peng; Zhou, Ming; Yang, Gang; Wang, Qin-Wen; Zeng, Yanjun

来源：Oncology Letters, 2014, 7(4): 1292-1296.

DOI：10.3892/ol.2014.1815

• stereotactic body radiation therapy
• lung tumor
• centrally-located

The application of high-dose irradiation to centrally-located lung tumors is generally considered to be of high risk in causing bronchial injury. The aim of the present retrospective study was to investigate the safety and efficacy of stereotactic body radiation therapy (SBRT) for patients with centrally-located lung tumors. In total, 28 patients who underwent SBRT for lung tumors within 2 cm of a major bronchus were retrospectively analyzed. The median total dose prescribed was 45 Gy (range, 36.3-52.5 Gy), the median fraction was 12 (range, 10-15) and the median dose per fraction was 3.6 Gy (range, 3-5 Gy). The median follow-up period for the surviving patients was 14 months (range, 10-41 months). The local control rate of SBRT was 100%, with a complete response (CR) rate of 32.1% (9/28); a partial response (PR) rate of 50% (14/28) and a stable disease (SD) rate of 17.9% (5/28). In total, 15 patients survived and 13 patients succumbed; 11 patients succumbed to tumor progression, one to congestive heart failure and one to a brain hemorrhage. The main side-effects included grade 2 esophagitis (17.9%; 5/28) atelectasis (10.7%; 3/28) and grade 2 late radiation pneumonitis (7.1%; 2/28). Severe late toxicity (>= grade 3) was not observed in any patient. SBRT is an effective and safe therapy for centrally-located lung tumors.

• 出版日期2014-4
• 单位中国人民解放军军事医学科学院; 中国人民解放军空军总医院; 北京工业大学